证券代码：300529 证券简称：健帆生物 公告编号：2025-068 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300529 证券简称：健帆生物 2、债券代码：123117 债券简称：健帆转债 （一）可转债发行情况 经中国证券监督管理委员会"证监许可[2020]3617 号"文同意注册，健帆生 物科技集团股份有限公司于 2021 年 6 月 23 日向不特定对象发行了 1,000.00 万张 可转换公司债券，每张面值 100 元，发行总额人民币 100,000.00 万元。本次向不 特定对象发行的可转债向公司在股权登记日收市后登记在册的原股东优先配售， 原股东优先配售后余额部分（含原股东放弃优先配售部分）采用网上向社会公众 投资者通过深交所交易系统发售的方式进行。对认购金额不足 100,000.00 万元的 1 3、转股价格：38.65 元/股 4、转股期限：2021 年 12 月 29 日至 2027 年 ...

上市企业：健帆生物（300529）、山外山（688410） 相关企业：淄博康贝医疗器械有限公司、重庆希尔康血液净化器材研发有限公司、威海威高生命科技有 限公司、天津优纳斯生物科技有限公司、天津市阳权医疗器械有限公司、苏州仝康医疗科技有限公司、 廊坊市爱尔医疗科技有限公司、河南省驼人医疗科技有限公司、广州康盛生物科技股份有限公司、佛山 市博新生物科技有限公司、成都欧赛医疗器械有限公司、北京中科太康科技有限公司、北京中科盛康科 技股份有限公司 关键词：血液灌流器产业链、血液灌流器发展背景、血液灌流器市场规模、血液灌流器竞争格局、血液 灌流器发展趋势 一、概述 内容概要：庞大的患者群体带动我国血液灌流器市场需求快速增长，据统计，2024年我国血液灌流器行 业市场规模达38.07亿元，同比增长13.24%，但目前我国终末期肾病患者的透析治疗率与欧美国家相比 仍有较大差距，未来，随着医疗水平的提高和医保覆盖范围的扩大，透析治疗率有望进一步提升，同 时，根据国家卫健委的操作流程，每周1次HA树脂血液灌流器与血液透析器串联治疗可显著提高维持性 血液透析患者的相关指标清除率，但目前患者的使用频率多为每月一次，提升空间较大。 ...

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

Financial Performance - In the first half of 2025, the company achieved revenue of 1.134 billion CNY, a year-on-year decrease of 24.15% [1] - Net profit for the same period was 389 million CNY, down 29.46% year-on-year [1] - Operating cash flow was 538 million CNY, exceeding net profit by 149 million CNY, indicating high-quality cash flow [1] - Gross margin stood at 79.82%, while net margin was 34.26%, reflecting strong overall profitability [1] Marketing Progress - In the nephrology sector, sales from kidney disease products reached 784.97 million CNY, accounting for 69.20% of total revenue [2] - The KHA series generated 79.98 million CNY in sales, a 27.34% increase year-on-year, covering over 700 hospitals [2] - The pHA series, launched in November 2023, achieved sales of 11.75 million CNY, with a remarkable growth of 374.22% [2] - In the hepatology sector, sales reached 131.53 million CNY, representing 11.59% of total revenue [2] - The critical care sector generated 142.31 million CNY, accounting for 12.54% of total revenue [3] Research and Development - R&D investment amounted to 97 million CNY, representing 8.59% of total revenue [5] - The company obtained 15 new patents, bringing the total to 393, including 111 invention patents [5] - Two products received CE certification under the new EU MDR regulations, allowing sales in EU countries [5] Dividend Policy - The company distributed a cash dividend of 620 million CNY for the 2024 fiscal year, with a payout ratio exceeding 75% [5] - Cumulative dividends since the company's IPO amount to 4.07 billion CNY, 2.9 times the amount raised through IPO and refinancing [5] Social Responsibility - The company donated cash and materials valued at 19.17 million CNY for charitable projects, reflecting its commitment to social responsibility [5] Future Outlook - The company plans to enhance its focus on the blood purification field and expand its international market presence [8] - It aims to increase the penetration rate of kidney products and improve clinical application frequency [11] - The company is exploring new business areas related to metabolic cardiovascular diseases and health management [15] - Future international business growth will be driven by academic promotion and partnerships with key hospitals [14]

Core Viewpoint - The article discusses the announcement of the second batch of selected units for the "Innovation Task of Biomedical Materials" by the Ministry of Industry and Information Technology, highlighting various innovative materials and their respective companies involved in their development [2][3]. Group 1: Polymer Materials - Key materials include Polyethylene Terephthalate, Phosphorylcholine-based Polymers, High Purity Acrylic Monomers, and High Oxygen Permeability Silicones [3][4]. - Companies involved in these materials include China Petrochemical Corporation, Weigao Group, and Jiangsu New Vision Advanced Functional Fiber Innovation Center [4][5]. - Other notable materials are Dendritic Light-sensitive Smart Materials and Anti-thrombus New Materials, with companies like Jiangsu Baisei Biotechnology and BoHui (Zhejiang) Biotechnology [3][6]. Group 2: Metal Materials - Key materials in this category include Ultra-fine Crystal Titanium Rod Wire, Porous Tantalum, Zirconium Niobium Alloys, and High-end Stainless Steel Wire [7][8]. - Companies such as Baoji Xinnuo Special Materials and Shenzhen Shigesaisi Medical Technology are involved in the production of these materials [9]. Group 3: Inorganic Non-metallic Materials - Important materials include Degradable Semi-hydrated Calcium Sulfate, Silicon Nitride Ceramics, and 3D Printing Zirconia Ceramic Inks [10][11]. - Companies like Zhongding Kairui Technology and Beijing Bansai Technology are engaged in the development of these materials [11].

Core Viewpoint - The financial performance of Jianfan Biological (300529) in the 2025 mid-year report shows significant declines in revenue and net profit, indicating potential challenges ahead for the company [1] Financial Performance Summary - The total operating revenue for the company is 1.134 billion yuan, a year-on-year decrease of 24.15% [1] - The net profit attributable to shareholders is 390 million yuan, down 29.46% year-on-year [1] - In Q2, the operating revenue is 587 million yuan, a decline of 21.92% year-on-year, while the net profit attributable to shareholders is 201 million yuan, down 24.95% year-on-year [1] - The gross profit margin is 79.82%, a decrease of 0.88% year-on-year, and the net profit margin is 34.26%, down 6.96% year-on-year [1] - Total selling, administrative, and financial expenses amount to 345 million yuan, accounting for 30.44% of revenue, an increase of 5.02% year-on-year [1] - Earnings per share is 0.51 yuan, a decrease of 26.09% year-on-year [1] Significant Financial Changes - Cash and cash equivalents decreased by 56.66% due to purchases of financial products and dividends [2] - Accounts receivable decreased by 53.17% as a result of improved management and credit policies [3] - Short-term borrowings decreased by 40.61% due to repayment of bank loans [4] - Contract liabilities increased by 133.0% due to an increase in customer prepayments [5] - Long-term borrowings increased by 30.96% due to new bank loans for biological materials projects [6] - Trading financial assets increased by 143.03% due to purchases of financial products [7] - Accounts receivable financing increased by 1225.7% due to an increase in bank acceptance bills held [8] - Deferred tax assets increased by 54.88% due to deductible temporary differences from deferred income and stock incentive expenses [9] - Employee compensation payable decreased by 53.32% due to bonus payments [10] - Other current liabilities increased by 157.63% due to an increase in customer prepayments [11] - Deferred income increased by 55.9% due to government subsidies related to assets [12] - Minority interests decreased by 138.99% due to losses from non-wholly owned subsidiaries [12] - Financial expenses increased by 151.3% due to adjustments in the funding structure and decreased interest income from deposits [12] - Income tax expenses decreased by 33.12% due to reduced profits [12] Business Evaluation - The company's return on invested capital (ROIC) for the previous year was 17.74%, indicating strong capital returns [12] - The net profit margin last year was 30.41%, suggesting high added value for products or services [12] - Historical data shows a median ROIC of 30.86% since the company went public, with the worst year being 2023 at 8.09% [12] - The company's business model relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers [12] Debt and Earnings Forecast - The company has a debt ratio of interest-bearing assets reaching 26.46% [12] - Analysts expect the company's performance in 2025 to reach 851 million yuan, with an average earnings per share of 1.06 yuan [12]

Group 1 - The core viewpoint of the report is that Jianfan Biological (300529.SZ) is rated as a "buy" due to its potential for long-term profitability despite short-term performance pressures [2] - The company is strengthening channel management, which may lead to short-term performance challenges [2] - Rapid expansion of new product lines is expected to enhance long-term profitability [2]

Group 1 - The core viewpoint of the news is that Jianfan Bio (300529.SZ) reported a decrease in institutional investor holdings in its A-shares, with a total of 51.87 million shares held by six institutions, representing 6.49% of the total share capital, down by 2.00 percentage points from the previous quarter [1] Group 2 - In the public fund sector, two public funds increased their holdings, including Huabao Zhongzheng Medical ETF and Southern Zhongzheng 500 ETF, with an increase ratio of 0.25% [2] - Two public funds decreased their holdings, namely, Zhaoshang Guozhen Biomedical Index A and Yifangda Growth Enterprise ETF, with a decrease ratio of 0.11% [2] - Six public funds did not disclose their holdings in the current period, including Guangda Baodexin Credit Enhancement Bond A and others [2] Group 3 - Regarding foreign investment, the Hong Kong Central Clearing Limited is noted as an institution that did not disclose its holdings in the current period [3]

（文章来源：每日经济新闻） 健帆生物（SZ 300529，收盘价：23.65元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收 入约11.34亿元，同比减少24.15%；归属于上市公司股东的净利润约3.9亿元，同比减少29.46%；基本每 股收益0.51元，同比减少26.09%。 ...

2024年1至12月份，健帆生物的营业收入构成为：医疗器械制造业占比99.71%，其他占比0.29%。 （文章来源：每日经济新闻） 健帆生物（SZ 300529，收盘价：23.65元）8月21日晚间发布公告称，公司第五届第三十一次董事会会 议于2025年8月21日在公司会议室以现场会议及通讯表决的方式召开。会议审议了《2025年半年度报 告》等文件。 ...